Angiotensin Receptor-Neprilysin Inhibition
- PMID: 28587583
- DOI: 10.1177/1074248416683049
Angiotensin Receptor-Neprilysin Inhibition
Abstract
The novel combination sacubitril/valsartan represents a new therapeutic approach in the management of heart failure. With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while avoiding the deleterious effect of angiotensin II receptors activation and thereby encompasses a beneficial impact of 2 important neurohormonal pathways activated in heart failure. As opposed to previously tested neprilysin inhibitors, sacubitril/valsartan represents a more effective method in reducing morbidity and mortality in heart failure, while preserving a safety profile comparable to well-established, standard, angiotensin-converting enzyme inhibitor's therapy.
Keywords: heart failure; neprilysin; sacubitril/valsartan.
Similar articles
-
Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?J Cardiovasc Pharmacol. 2020 Feb;75(2):105-107. doi: 10.1097/FJC.0000000000000782. J Cardiovasc Pharmacol. 2020. PMID: 31815825 No abstract available.
-
Sacubitril/valsartan (Entresto) for heart failure.Med Lett Drugs Ther. 2015 Aug 3;57(1474):107-9. Med Lett Drugs Ther. 2015. PMID: 26218791 Review. No abstract available.
-
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.Circulation. 2019 Mar 12;139(11):1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077. Circulation. 2019. PMID: 30586756 Clinical Trial.
-
In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?J Cardiovasc Pharmacol. 2019 Jul;74(1):1-3. doi: 10.1097/FJC.0000000000000685. J Cardiovasc Pharmacol. 2019. PMID: 31274835 No abstract available.
-
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.Heart. 2016 Sep 1;102(17):1342-7. doi: 10.1136/heartjnl-2014-306775. Epub 2016 May 20. Heart. 2016. PMID: 27207980 Free PMC article. Review.
Cited by
-
Assessment of acute heart failure prognosis: the promising role of prognostic models and biomarkers.Heart Fail Rev. 2022 Mar;27(2):655-663. doi: 10.1007/s10741-021-10122-9. Epub 2021 May 25. Heart Fail Rev. 2022. PMID: 34036472 Review.
-
Recent major advances in cardiovascular pharmacotherapy.Eur J Clin Pharmacol. 2018 Jul;74(7):853-862. doi: 10.1007/s00228-018-2453-1. Epub 2018 Mar 27. Eur J Clin Pharmacol. 2018. PMID: 29589064 Review.
-
The efficacy and safety of Sacubitril/Valsartan in the treatment of chronic heart failure: a meta-analysis.Am J Transl Res. 2021 Nov 15;13(11):12114-12128. eCollection 2021. Am J Transl Res. 2021. PMID: 34956440 Free PMC article. Review.
-
Changes in urinary output due to concomitant administration of sacubitril/valsartan and atrial natriuretic peptide in patients with heart failure: a multicenter retrospective cohort study.J Pharm Health Care Sci. 2024 Sep 16;10(1):56. doi: 10.1186/s40780-024-00379-1. J Pharm Health Care Sci. 2024. PMID: 39285448 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
